Joel S Raichlen
Overview
Explore the profile of Joel S Raichlen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
1815
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ebrahimi A, Raichlen J, Pointon A, Gottfridsson C, Munley J, Hockings P, et al.
Expert Opin Drug Saf
. 2020 Feb;
19(3):281-294.
PMID: 32064957
: Drug-induced myocardial dysfunction is an important safety concern during drug development. Oncology compounds can cause myocardial dysfunction, leading to decreased left ventricular ejection fraction and heart failure via several...
2.
Verbree-Willemsen L, Zhang Y, Gijsberts C, Schoneveld A, Wang J, Lam C, et al.
Int J Cardiol
. 2018 Jun;
271:247-253.
PMID: 29898827
Background: Statins are thought to have pleiotropic properties, including anticoagulant effects, in addition to reducing lipoprotein (LDL) levels. Plasma extracellular vesicles (EVs) are small bilayer membrane vesicles involved in various...
3.
Stein E, Dann E, Wiegman A, Skovby F, Gaudet D, Sokal E, et al.
J Am Coll Cardiol
. 2017 Aug;
70(9):1162-1170.
PMID: 28838366
Background: Homozygous familial hypercholesterolemia (HoFH), a rare genetic disorder, is characterized by extremely elevated levels of low-density lipoprotein cholesterol (LDL-C) and accelerated atherosclerotic cardiovascular disease. Statin treatment starts at diagnosis,...
4.
Puri R, Ballantyne C, Hoogeveen R, Shao M, Barter P, Libby P, et al.
Atherosclerosis
. 2017 Jun;
263:137-144.
PMID: 28641153
Background & Aims: Lipoprotein(a) [Lp(a)] is a low-density lipoprotein (LDL)-like particle that associates with major adverse cardiovascular events (MACE). We examined relationships between Lp(a) measurements and changes in coronary atheroma...
5.
Braamskamp M, Langslet G, McCrindle B, Cassiman D, Francis G, Gagne C, et al.
Circulation
. 2017 Jun;
136(4):359-366.
PMID: 28592434
Background: Heterozygous familial hypercholesterolemia (HeFH) is an autosomal dominant disorder leading to premature atherosclerosis. Children with HeFH exhibit early signs of atherosclerosis manifested by increased carotid intima-media thickness (IMT). In...
6.
Gottfridsson C, Panfilov S, Ebrahimi A, Gigger E, Pollard C, Henderson S, et al.
Expert Opin Drug Saf
. 2016 Nov;
16(2):215-225.
PMID: 27830951
Changes in blood pressure (BP) are now proactively examined throughout the drug development process as an integral aspect of safety monitoring. This is because hypertension is a very strong risk...
7.
Braamskamp M, Langslet G, McCrindle B, Cassiman D, Francis G, Gagne C, et al.
J Clin Lipidol
. 2015 Dec;
9(6):741-750.
PMID: 26687694
Objective: Heterozygous familial hypercholesterolemia (HeFH) is an autosomal dominant disorder leading to premature atherosclerosis. Guidelines recommend initiating statins early to reduce low-density lipoprotein cholesterol (LDL-C). Studies have evaluated rosuvastatin in...
8.
Puri R, Nissen S, Shao M, Ballantyne C, Barter P, Chapman M, et al.
JACC Cardiovasc Imaging
. 2014 Sep;
7(10):1013-22.
PMID: 25240453
Objectives: The study sought to explore sex-related differences in coronary atheroma regression following high-intensity statin therapy. Background: Guidelines now recommend high-intensity statins in all individuals with atherosclerotic cardiovascular disease. Methods:...
9.
Puri R, Nissen S, Shao M, Ballantyne C, Barter P, Chapman M, et al.
Arterioscler Thromb Vasc Biol
. 2014 Sep;
34(11):2465-72.
PMID: 25212234
Objectives: Patients with acute coronary syndromes (ACS) display diffuse coronary atheroma instability and heightened risk of early and late recurrent coronary events. We compared the long-term antiatherosclerotic efficacy of high-intensity...
10.
Stegman B, Puri R, Cho L, Shao M, Ballantyne C, Barter P, et al.
Diabetes Care
. 2014 Sep;
37(11):3114-20.
PMID: 25190674
Objective: Although statins can induce coronary atheroma regression, this benefit has yet to be demonstrated in diabetic individuals. We tested the hypothesis that high-intensity statin therapy may promote coronary atheroma...